WST West Pharmaceutical Services Inc
Price (delayed)
$210.91
Market cap
$15.25B
P/E Ratio
31.25
Dividend/share
$0.82
EPS
$6.75
Enterprise value
$15.07B
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe,
Highlights
The stock's price to earnings (P/E) is 34% less than its 5-year quarterly average of 47.7 and 34% less than its last 4 quarters average of 47.6
WST's debt is down by 2.2% year-on-year
The net income has contracted by 17% YoY
WST's EPS is down by 15% year-on-year
Key stats
What are the main financial stats of WST
Market
Valuations
Earnings
Shares outstanding
72.3M
Market cap
$15.25B
Enterprise value
$15.07B
Price to earnings (P/E)
31.25
Price to book (P/B)
5.69
Price to sales (P/S)
5.32
EV/EBIT
24.98
EV/EBITDA
19.86
EV/Sales
5.21
Revenue
$2.89B
Gross profit
$998.5M
Operating income
$569.9M
Net income
$492.7M
EBIT
$603.2M
EBITDA
$758.6M
Free cash flow
$276.4M
Per share
Balance sheet
Liquidity
EPS
$6.75
EPS diluted
$6.69
Free cash flow per share
$3.79
Book value per share
$37.04
Revenue per share
$39.63
TBVPS
$48.31
Total assets
$3.64B
Total liabilities
$961.1M
Debt
$302.3M
Equity
$2.68B
Working capital
$987.7M
Debt to equity
0.11
Current ratio
2.79
Quick ratio
1.88
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
26.2%
Gross margin
34.5%
Net margin
17%
Operating margin
19.7%
Return on assets
13.7%
Return on equity
18.4%
Return on invested capital
22.4%
Return on capital employed
19.5%
Return on sales
20.8%
Dividend yield
0.39%
DPS
$0.82
Payout ratio
12.1%
WST stock price
How has the West Pharmaceutical Services stock price performed over time
Intraday
3.56%
1 week
-1.78%
1 month
-38.81%
1 year
-40.79%
YTD
-35.61%
QTD
-35.61%
Financial performance
How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.89B
Gross profit
$998.5M
Operating income
$569.9M
Net income
$492.7M
Gross margin
34.5%
Net margin
17%
The net income has contracted by 17% YoY
WST's operating income is down by 16% YoY
WST's net margin is down by 15% year-on-year and by 2.3% since the previous quarter
The operating margin has declined by 14% year-on-year
Growth
What is West Pharmaceutical Services's growth rate over time
Valuation
What is West Pharmaceutical Services stock price valuation
P/E
31.25
P/B
5.69
P/S
5.32
EV/EBIT
24.98
EV/EBITDA
19.86
EV/Sales
5.21
The stock's price to earnings (P/E) is 34% less than its 5-year quarterly average of 47.7 and 34% less than its last 4 quarters average of 47.6
WST's EPS is down by 15% year-on-year
The price to book (P/B) is 45% lower than the 5-year quarterly average of 10.3 and 38% lower than the last 4 quarters average of 9.2
WST's equity is down by 7% year-on-year and by 2.5% since the previous quarter
The P/S is 41% below the 5-year quarterly average of 9.0 and 37% below the last 4 quarters average of 8.5
Efficiency
How efficient is West Pharmaceutical Services business performance
WST's return on invested capital is down by 22% year-on-year and by 3.9% since the previous quarter
WST's return on sales is down by 15% year-on-year
The company's return on assets fell by 13% YoY
West Pharmaceutical Services's ROE has decreased by 13% YoY
Dividends
What is WST's dividend history
DPS
$0.82
Dividend yield
0.39%
Payout ratio
12.1%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did West Pharmaceutical Services financials performed over time
West Pharmaceutical Services's quick ratio has decreased by 7% YoY and by 4.6% from the previous quarter
West Pharmaceutical Services's current ratio has decreased by 7% QoQ and by 3.1% YoY
WST's debt is 89% smaller than its equity
WST's equity is down by 7% year-on-year and by 2.5% since the previous quarter
WST's debt is down by 2.2% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.